VCYT · Insider Trading
Veracyte, Inc.
Every open-market purchase and sale reported by VCYT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-29 | Jonathan Wygant | VP, Chief Accounting Officer | F | −1,306 | −$65.70K |
| 2026-10-28 | Karin Eastham | Director | MIXED | −4,850 | −$472.47K |
| 2026-10-28 | Jens Holstein | Director | MIXED | — | −$198.00K |
| 2026-10-20 | Muna Bhanji | Director | Sell | −1,864 | −$81.46K |
| 2026-09-22 | John Leite | Global Chief Commercial Off | Sell | −4,015 | −$160.60K |
| 2026-09-16 | Jens Holstein | Director | Sell | −5,000 | −$204.75K |
| 2026-09-04 | Marc Stapley | Chief Executive Officer | F | −8,782 | −$394.14K |
| 2026-09-04 | Phillip G. Febbo | Chief Scientific & Med Officer | MIXED | −16,749 | −$727.73K |
| 2026-09-04 | Annie McGuire | EVP, General Counsel | MIXED | −6,469 | −$284.50K |
| 2026-09-04 | Jonathan Wygant | VP, Chief Accounting Officer | F | −1,361 | −$61.08K |
| 2026-09-04 | Rebecca Chambers | Chief Financial Officer | MIXED | −7,255 | −$319.10K |
| 2026-09-04 | John Leite | Global Chief Commercial Off | F | −3,961 | −$177.77K |
| 2026-09-03 | Muna Bhanji | Director | Sell | −1,864 | −$80.10K |
| 2026-06-22 | Karin Eastham | Director | Sell | −3,729 | −$197.23K |
| 2026-06-15 | Robert S Epstein | Director | A | +5,272 | — |
| 2026-06-15 | Eliav Barr | Director | A | +5,272 | — |
| 2026-06-15 | Thomas F. Miller | Director | A | +5,272 | — |
| 2026-06-15 | Jens Holstein | Director | A | +5,272 | — |
| 2026-06-15 | Evan/ Fa Jones | Director | A | +5,272 | — |
| 2026-06-15 | David Brent Shafer | Director | A | +5,272 | — |
| 2026-06-15 | Karin Eastham | Director | A | +5,272 | — |
| 2026-06-15 | Muna Bhanji | Director | A | +5,272 | — |
| 2026-06-04 | John Leite | Global Chief Commercial Off | MIXED | −18,034 | −$893.75K |
| 2026-06-04 | Jonathan Wygant | VP, Chief Accounting Officer | F | −1,361 | −$65.06K |
| 2026-06-04 | Rebecca Chambers | Chief Financial Officer | MIXED | −7,254 | −$353.61K |
| 2026-06-04 | Annie McGuire | EVP, General Counsel | MIXED | −6,468 | −$315.39K |
| 2026-06-04 | Marc Stapley | Chief Executive Officer | MIXED | −9,012 | −$2.30M |
| 2026-06-04 | Phillip G. Febbo | Chief Scientific & Med Officer | F | −3,730 | −$178.29K |
| 2026-05-27 | Jonathan Wygant | VP, Chief Accounting Officer | MIXED | — | −$494.42K |
| 2026-05-22 | Robert S Epstein | Director | Sell | −10,000 | −$440.13K |
| 2026-05-08 | Annie McGuire | SVP, General Counsel | Sell | −10,204 | −$398.21K |
| 2026-04-14 | Kevin Richard Haas | Chief Dev and Tech Officer | A | +44,221 | — |
| 2026-03-10 | Rebecca Chambers | Chief Financial Officer | A | +49,338 | — |
| 2026-03-10 | Phillip G. Febbo | Chief Scientific & Med Officer | A | +36,181 | — |
| 2026-03-10 | Marc Stapley | Chief Executive Officer | A | +92,099 | — |
| 2026-03-10 | Jonathan Wygant | VP, Chief Accounting Officer | A | +10,525 | — |
| 2026-03-10 | John Leite | Chief Commercial Officer-CLIA | A | +42,759 | — |
| 2026-03-10 | Annie McGuire | SVP, General Counsel | A | +59,206 | — |
| 2026-03-06 | Marc Stapley | Chief Executive Officer | Sell | −45,523 | −$1.64M |
| 2026-03-06 | John Leite | Chief Commercial Officer-CLIA | Sell | −5,260 | −$185.08K |
| 2026-03-06 | Annie McGuire | SVP, General Counsel | Sell | −6,658 | −$236.72K |
| 2026-03-06 | Rebecca Chambers | Chief Financial Officer | Sell | −18,341 | −$662.87K |
| 2026-03-04 | Annie McGuire | SVP, General Counsel | F | −6,902 | −$248.54K |
| 2026-03-04 | John Leite | Chief Commercial Officer-CLIA | F | −7,517 | −$270.69K |
| 2026-03-04 | Marc Stapley | Chief Executive Officer | F | −19,455 | −$700.57K |
| 2026-03-04 | Jonathan Wygant | VP, Chief Accounting Officer | F | −3,006 | −$108.25K |
| 2026-03-04 | Phillip G. Febbo | Chief Scientific & Med Officer | MIXED | −19,460 | −$702.75K |
| 2026-03-04 | Rebecca Chambers | Chief Financial Officer | F | −7,234 | −$260.50K |
| 2026-03-02 | Rebecca Chambers | Chief Financial Officer | MIXED | +47,275 | −$466.90K |
| 2026-03-02 | John Leite | Chief Commercial Officer-CLIA | MIXED | +38,244 | −$345.07K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Marc Stapley | Chief Executive Officer | 432,073 | $10.32M |
| Rebecca Chambers | Chief Financial Officer | 166,025 | $3.96M |
| Phillip G. Febbo | Chief Scientific & Med Officer | 135,753 | $3.24M |
| Annie McGuire | EVP, General Counsel | 134,414 | $3.21M |
| John Leite | Global Chief Commercial Off | 124,329 | $2.97M |
| Robert S Epstein | Director | 57,718 | $1.38M |
| Eliav Barr | Director | 56,461 | $1.35M |
| Kevin Richard Haas | Chief Dev and Tech Officer | 44,221 | $1.06M |
| Jonathan Wygant | VP, Chief Accounting Officer | 41,920 | $1.00M |
| Muna Bhanji | Director | 40,854 | $975.39K |
| Evan/ Fa Jones | Director | 34,634 | $826.89K |
| David Brent Shafer | Director | 31,100 | $742.51K |
| Thomas F. Miller | Director | 31,100 | $742.51K |
| Jens Holstein | Director | 27,471 | $655.87K |
| Karin Eastham | Director | 14,447 | $344.92K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the VCYT quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.